2月24日，美股夜盘时段，Vir Biotechnology涨超57%，Q4营收同比增长417%，并宣布前列腺癌药物试验获积极结果并与安斯泰来达成重磅合作；
Hims & Hers Health跌超8%，Q4营收同比增长28%，2026年Q1营收指引令人失望。
2月24日，美股夜盘时段，Vir Biotechnology涨超57%，Q4营收同比增长417%，并宣布前列腺癌药物试验获积极结果并与安斯泰来达成重磅合作；
Hims & Hers Health跌超8%，Q4营收同比增长28%，2026年Q1营收指引令人失望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
